ADMA - ADMA Biologics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
4.88
+0.06 (+1.24%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close4.82
Open4.82
Bid0.00 x 0
Ask0.00 x 0
Day's Range4.80 - 4.97
52 Week Range2.01 - 5.50
Volume30,681
Avg. Volume114,565
Market Cap221.148M
Beta2.71
PE Ratio (TTM)N/A
EPS (TTM)-1.91
Earnings DateMay 10, 2018 - May 14, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.13
Trade prices are not sourced from all markets
  • ADMA Biologics Inc (NASDAQ:ADMA): Should The Recent Earnings Drop Worry You?
    Simply Wall St.last month

    ADMA Biologics Inc (NASDAQ:ADMA): Should The Recent Earnings Drop Worry You?

    Assessing ADMA Biologics Inc’s (NASDAQ:ADMA) past track record of performance is a useful exercise for investors. It allows us to understand whether the company has met or exceed expectations, whichRead More...

  • When Will ADMA Biologics Inc (NASDAQ:ADMA) Turn A Profit?
    Simply Wall St.last month

    When Will ADMA Biologics Inc (NASDAQ:ADMA) Turn A Profit?

    ADMA Biologics Inc’s (NASDAQ:ADMA): ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-based biologics for the treatment of immune deficiencies and infectious diseases. On 31 December 2017,Read More...

  • GlobeNewswire2 months ago

    ADMA Biologics Reports Full Year 2017 Financial Results

    RAMSEY, N.J. and BOCA RATON, Fla., March 05, 2018-- ADMA Biologics, Inc., a vertically integrated commercial biopharmaceutical and specialty immunoglobulin company that manufactures, markets and develops ...

  • GlobeNewswire2 months ago

    ADMA Biologics to Present at Raymond James’ 39th Annual Institutional Investors Conference

    RAMSEY, N.J. and BOCA RATON, Fla., Feb. 27, 2018-- ADMA Biologics, Inc., a vertically integrated commercial biopharmaceutical company that develops, manufactures and markets specialty plasma-based biologics ...

  • Does ADMA Biologics Inc’s (NASDAQ:ADMA) CEO Salary Compared Well With Others?
    Simply Wall St.3 months ago

    Does ADMA Biologics Inc’s (NASDAQ:ADMA) CEO Salary Compared Well With Others?

    Leading ADMA Biologics Inc (NASDAQ:ADMA) as the CEO, Adam Grossman took the company to a valuation of $178.55M. Recognizing whether CEO incentives are aligned with shareholders is a crucial partRead More...

  • Does ADMA Biologics Inc’s (NASDAQ:ADMA) Past Performance Indicate A Weaker Future?
    Simply Wall St.4 months ago

    Does ADMA Biologics Inc’s (NASDAQ:ADMA) Past Performance Indicate A Weaker Future?

    Understanding ADMA Biologics Inc’s (NASDAQ:ADMA) performance as a company requires examining more than earnings from one point in time. Today I will take you through a basic sense check toRead More...

  • ACCESSWIRE4 months ago

    Wired News – ADMA Files Biologics License Application for Its Third Plasma Collection Center

    Stock Monitor: Can-Fite BioPharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / December 13, 2017 / Active-Investors issued a free report on ADMA Biologics, Inc. (NASDAQ: ADMA ) ("ADMA"), ...

  • Capital Cube5 months ago

    ETFs with exposure to ADMA Biologics, Inc. : November 29, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to ADMA Biologics, Inc. Here are 5 ETFs with the largest exposure to ADMA-US. Comparing the performance and risk of ADMA Biologics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • ADMA Biologics Inc (ADMA): What Does It Mean For Your Portfolio?
    Simply Wall St.5 months ago

    ADMA Biologics Inc (ADMA): What Does It Mean For Your Portfolio?

    For ADMA Biologics Inc’s (NASDAQ:ADMA) shareholders, and also potential investors in the stock, understanding how the stock’s risk and return characteristics can impact your portfolio is important. Every stock inRead More...

  • Zacks Small Cap Research5 months ago

    ADMA: Third Quarter 2017 Financial Results and Corporate Update

    By John Vandermosten, CFA NASDAQ:ADMA ADMA Biologics, Inc. (NASDAQ: ADMA) experienced its first full quarter merged with the Biotest Therapy Business Unit (BTBU) and reported 3Q:17 results on November ...

  • Are ADMA Biologics Inc’s (ADMA) Interest Costs Too High?
    Simply Wall St.5 months ago

    Are ADMA Biologics Inc’s (ADMA) Interest Costs Too High?

    ADMA Biologics Inc (NASDAQ:ADMA) is a small-cap stock with a market capitalization of USD $61.90M. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies,Read More...

  • ADMA Biologics, Inc. :ADMA-US: Earnings Analysis: Q3, 2017 By the Numbers : November 8, 2017
    Capital Cube5 months ago

    ADMA Biologics, Inc. :ADMA-US: Earnings Analysis: Q3, 2017 By the Numbers : November 8, 2017

    Categories: Yahoo FinanceGet free summary analysis ADMA Biologics, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of ADMA Biologics, Inc. – Novavax, Inc. and Vical Incorporated (NVAX-US and VICL-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 4.73 million, Net ... Read more (Read more...)

  • Associated Press6 months ago

    Adma Biologics posts 3Q profit

    The Ramsey, New Jersey-based company said it had net income of 59 cents per share. The infectious disease drug developer posted revenue of $4.7 million in the period. In the final minutes of trading on ...

  • Why ADMA Biologics Inc (ADMA) Could Be A Buy
    Simply Wall St.6 months ago

    Why ADMA Biologics Inc (ADMA) Could Be A Buy

    ADMA Biologics Inc (NASDAQ:ADMA), a biotechnology company based in United States, received a lot of attention from a substantial price movement on the NasdaqCM in the over the last fewRead More...

  • Capital Cube6 months ago

    ETFs with exposure to ADMA Biologics, Inc. : October 25, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to ADMA Biologics, Inc. Here are 5 ETFs with the largest exposure to ADMA-US. Comparing the performance and risk of ADMA Biologics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Capital Cube7 months ago

    ETFs with exposure to ADMA Biologics, Inc. : September 28, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to ADMA Biologics, Inc. Here are 5 ETFs with the largest exposure to ADMA-US. Comparing the performance and risk of ADMA Biologics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • ADMA Biologics, Inc. :ADMA-US: Earnings Analysis: Q2, 2017 By the Numbers : September 5, 2017
    Capital Cube8 months ago

    ADMA Biologics, Inc. :ADMA-US: Earnings Analysis: Q2, 2017 By the Numbers : September 5, 2017

    Categories: Yahoo FinanceGet free summary analysis ADMA Biologics, Inc. reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of ADMA Biologics, Inc. – Novavax, Inc., Repligen Corporation, Vical Incorporated and CEL-SCI Corporation (NVAX-US, RGEN-US, VICL-US and CVM-US) that have also reported for this period. Highlights Summary numbers: ... Read more (Read more...)

  • Zacks Small Cap Research8 months ago

    ADMA: Second Quarter 2017 Financial Results and Corporate Update

    By John Vandermosten, CFA NASDAQ:ADMA ADMA Biologics, Inc. (NASDAQ:ADMA) closed the Biotest Therapy Business Unit (BTBU) transaction on June 6, 2017 and began the process of remedying the outstanding discrepancies ...